The pharmaceutical company Oasmia Pharmaceutical has recently concluded a phase
I/II study on cancer patients with its product Paclical®. The purpose was
investigation of different doses and side-effects. The results fulfilled all
the company's expectations.
Cancer is one of the most common diseases. WHO reports that 11 million people
are diagnosed with cancer each year. There is a constant need for new drugs and
treatments. Oasmia develops pharmaceuticals and opens up for new methods in
cancer treatment.
During the recent years, Oasmia have carried out a study on cancer patients.
The results will be presented shortly.
The company will initiate Phase III-studies on patients starting the third
quarter 2007.
Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest
concepts in bio-organic chemistry. The company idea is to improve treatment of
serious conditions, with a focus on oncology. This is done through development
of semi-synthesised substances to a new generation of effective pharmaceuticals
for various areas of therapy. Oasmia is noted on the NGM Nordic MTF
More information is available at www.ngm.se or at www.oasmia.com.
For more information, contact info@oasmia.com or call +46 18 50 54 40.
